Capped antithrombin III dosing is cost effective in the management of asparaginase-associated thrombosis

被引：2
|
作者：
Young, Jennifer [1 ]
Sawyer, Jaclyn [1 ]
Jenkins, Meredith [1 ]
O'Brien, Maureen [2 ,3 ]
Luchtman-Jones, Lori [3 ,4 ]
Breese, Erin H. [2 ,3 ]
机构：
[1] Cincinnati Childrens Hosp Med Ctr, Div Pharm, 3333 Burnet Ave,MLC 15010, Cincinnati, OH 45209 USA
[2] Cincinnati Childrens Hosp Med Ctr, Div Oncol, Canc & Blood Dis Inst, Cincinnati, OH 45209 USA
[3] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA
[4] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Div Hematol, Cincinnati, OH 45209 USA
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷 / 06期
关键词：
antithrombin III; asparaginase-induced thrombosis; capped antithrombin III; ACUTE LYMPHOBLASTIC-LEUKEMIA; VENOUS THROMBOEMBOLISM; SUPPLEMENTATION;
D O I：
10.1002/pbc.27719
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Asparaginase therapy induces a transient antithrombin III (ATIII) deficiency, which contributes to the risk of asparaginase-induced thrombosis. At Cincinnati Children's Hospital Medical Center, management of asparaginase-induced thrombosis includes ATIII supplementation during therapeutic anticoagulation with enoxaparin. Due to the expense associated with ATIII, a capped dosing approach for ATIII was evaluated in this population. Peak ATIII levels were obtained following capped doses to evaluate response. In this pilot evaluation, 11 patients received a total of 138 capped doses for a total cost savings of $803 782. This pilot evaluation represents the first reported analysis of capped ATIII dosing in oncology patients.
引用
收藏
页数：3
相关论文
共 39 条
  • [31] Low Molecular Weight Heparin Vs Direct Oral Anticoagulants (Apixaban, Edoxaban and Rivaroxaban) for the Treatment of Cancer Associated Thrombosis: A Cost- Effective Analysis
    Gulati, Shuchi
    Elsisi, Zizi
    Deoghare, Smruti
    Eckman, Mark
    BLOOD, 2019, 134
  • [32] Which interventions are cost-effective for the management of whiplash-associated and neck pain-associated disorders? A systematic review of the health economic literature by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration
    van der Velde, Gabrielle
    Yu, Hainan
    Paulden, Mike
    Cote, Pierre
    Varatharajan, Sharanya
    Shearer, Heather M.
    Wong, Jessica J.
    Randhawa, Kristi
    Southerst, Danielle
    Mior, Silvano
    Sutton, Deborah
    Jacobs, Craig
    Taylor-Vaisey, Anne
    SPINE JOURNAL, 2016, 16 (12): : 1582 - 1597
  • [33] A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT)
    Noble, Simon I.
    Nelson, Annmarie
    Fitzmaurice, David
    Bekkers, Marie-Jet
    Baillie, Jessica
    Sivell, Stephanie
    Canham, Joanna
    Smith, Joanna D.
    Casbard, Angela
    Cohen, Ander
    Cohen, David
    Evans, Jessica
    Fletcher, Kate
    Johnson, Miriam
    Maraveyas, Anthony
    Prout, Hayley
    Hood, Kerenza
    HEALTH TECHNOLOGY ASSESSMENT, 2015, 19 (83) : 1 - +
  • [34] The Low-Cost, Long-Term Indwelling Pleural Catheter (LunGO): An Inexpensive and Effective Alternative for the Management of Dyspnea Associated with Malignant Pleural Effusions
    Louro Bruno de Abreu, Igor Renato
    Bina Biazzotto, Antonio Flavio
    Santos, Mariana Alves
    Correia de Souza, Angela Alves
    Abrao, Fernando Conrado
    Carvaiho Cavalcante, Maria Gabriela
    RESPIRATION, 2019, 98 (02) : 151 - 156
  • [35] A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective Anticoagulation Length with low molecular weight heparin In the treatment of Cancer Associated Thrombosis (ALICAT): study protocol for a mixed-methods study
    Smith, Joanna D.
    Baillie, Jessica
    Baglin, Trevor
    Griffiths, Gareth O.
    Casbard, Angela
    Cohen, David
    Fitzmaurice, David A.
    Hood, Kerenza
    Rose, Peter
    Cohen, Alexander T.
    Johnson, Miriam
    Maraveyas, Anthony
    Bell, John
    Toone, Harold
    Nelson, Annmarie
    Noble, Simon I.
    TRIALS, 2014, 15
  • [36] A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective Anticoagulation Length with low molecular weight heparin In the treatment of Cancer Associated Thrombosis (ALICAT): study protocol for a mixed-methods study
    Joanna D Smith
    Jessica Baillie
    Trevor Baglin
    Gareth O Griffiths
    Angela Casbard
    David Cohen
    David A Fitzmaurice
    Kerenza Hood
    Peter Rose
    Alexander T Cohen
    Miriam Johnson
    Anthony Maraveyas
    John Bell
    Harold Toone
    Annmarie Nelson
    Simon I Noble
    Trials, 15
  • [37] Is PET-CT guided management for patients with locally advanced head and neck squamous cell cancer (HNSCC) cost-effective? Results from a UK non-inferiority phase III randomized trial.
    Smith, Alison Florence
    Hall, Peter
    Hulme, Claire
    Dunn, Janet
    Rahman, Joy K.
    McConkey, Christopher C.
    Mehanna, Hisham
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] A three-group study, internet-based, face-to-face based and standard- management after acute whiplash associated disorders (WAD) – choosing the most efficient and cost-effective treatment: study protocol of a randomized controlled trial
    Anne Söderlund
    Annika Bring
    Pernilla Åsenlöf
    BMC Musculoskeletal Disorders, 10
  • [39] A three-group study, internet-based, face-to-face based and standard-management after acute whiplash associated disorders (WAD) - choosing the most efficient and cost-effective treatment: study protocol of a randomized controlled trial
    Soderlund, Anne
    Bring, Annika
    Asenlof, Pernilla
    BMC MUSCULOSKELETAL DISORDERS, 2009, 10
1234